Compare Stocks → You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMSNASDAQ:ALDXNASDAQ:MBIONASDAQ:PHASNASDAQ:SBBP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AALDXAldeyra Therapeutics$3.98+0.3%$3.56$1.42▼$11.97$234.42M1.51592,505 shs432,642 shsMBIOMustang Bio$0.37-2.6%$1.04$0.33▼$8.17$3.86M1.58177,756 shs199,542 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/ASBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ALDXAldeyra Therapeutics+0.25%-9.55%+39.65%+29.22%-61.51%MBIOMustang Bio-3.39%-32.20%-64.50%-72.52%-90.82%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+25.00%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%Now Open: Crypto emergency update (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AALDXAldeyra Therapeutics2.16 of 5 stars3.53.00.00.02.62.50.0MBIOMustang Bio1.8568 of 5 stars3.55.00.00.02.30.00.0PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas PharmaceuticalsN/AN/AN/AN/AALDXAldeyra Therapeutics3.00Buy$9.33134.51% UpsideMBIOMustang Bio3.00Buy$17.254,549.60% UpsidePHASPhaseBio PharmaceuticalsN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest ADMS, ALDX, PHAS, MBIO, and SBBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49ALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/AMBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/AALDXAldeyra Therapeutics-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%5/2/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ASBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ALatest ADMS, ALDX, PHAS, MBIO, and SBBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17ALDXAldeyra TherapeuticsN/A6.646.64MBIOMustang BioN/A0.740.74PHASPhaseBio PharmaceuticalsN/A0.470.47SBBPStrongbridge Biopharma0.383.002.95OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%ALDXAldeyra Therapeutics59.71%MBIOMustang Bio9.95%PHASPhaseBio Pharmaceuticals49.02%SBBPStrongbridge Biopharma52.03%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%ALDXAldeyra Therapeutics7.30%MBIOMustang Bio2.10%PHASPhaseBio Pharmaceuticals9.90%SBBPStrongbridge Biopharma5.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableALDXAldeyra Therapeutics1558.90 million54.60 millionOptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableADMS, ALDX, PHAS, MBIO, and SBBP HeadlinesSourceHeadlineRising Investment in Patient Support Drives a Greater Biopharma Focus on Measurementfiercepharma.com - March 5 at 7:51 AMMatinas BioPharma Holdings Inc (MTNB)investing.com - February 10 at 12:33 PMLytix Biopharma As Share Price (LYTIX.OL)lse.co.uk - November 15 at 2:21 AMAmbrx Biopharma Inc AMAMmorningstar.com - November 4 at 7:36 PMBiopharma’s rapid transition to omnichannel marketingpharmaphorum.com - September 11 at 9:18 AMHILS Hillstream BioPharma, Inc.seekingalpha.com - August 19 at 3:55 PMABUS - Arbutus Biopharma Corporationfinance.yahoo.com - July 1 at 12:38 PMThe Nominees for Best Biopharma CEO of 2015 Are...thestreet.com - April 25 at 8:23 AMDay One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenibmarketwatch.com - January 11 at 9:43 PMBiopharma Soars to the Computational Cloudsgenengnews.com - October 9 at 12:47 PMAccord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patientsmarkets.businessinsider.com - September 22 at 10:04 AMStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ...apnews.com - September 23 at 5:49 PMStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.finance.yahoo.com - September 23 at 5:49 PMPress Release: Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharmasharecast.com - September 14 at 5:56 PMXeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharmastockhouse.com - September 14 at 5:56 PMStrongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ...apnews.com - September 9 at 12:31 PMLeading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ...apnews.com - August 31 at 7:54 AMSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeristmcnet.com - August 31 at 7:54 AMSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xerisfinance.yahoo.com - August 31 at 7:54 AMStrongbridge Biopharma plc (NASDAQ: SBBP) Have Dropped -20.16% YTD, What Will Happen Nextmarketingsentinel.com - August 14 at 7:50 AMStrongbridge Biopharma: Q2 Earnings Snapshotsfgate.com - August 5 at 8:43 AMStrongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 5 at 8:43 AMStrongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statementfinance.yahoo.com - August 2 at 9:34 AMStrongbridge Biopharma plc (NASDAQ:SBBP) Shares Plunges -8.08% In A Week – But Can It Keep Rising?marketingsentinel.com - July 31 at 9:50 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Penny Stock Quantum-Si Incorporated Readies For Lift-OffApril 9, 2024 7:14 AMView Penny Stock Quantum-Si Incorporated Readies For Lift-OffAll Headlines Company DescriptionsAdamas PharmaceuticalsNASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Aldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Strongbridge BiopharmaNASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.